“`html
COPENHAGEN, February 29, 2024 – Brace yourself: the blockbuster weight-loss drugs Ozempic and Wegovy might not keep their meteoric rise going forever. Danish pharmaceutical giant Novo Nordisk is bracing for a potential sales slowdown, predicting a drop of as much as 13 percent in 2026.
Pricing Pressures Loom large for Weight Loss Market
Novo Nordisk expects sales to possibly decrease by up to 13 percent in 2026 as the prices of Ozempic and Wegovy face increased scrutiny.
- Novo Nordisk forecasts a potential sales decline of up to 13 percent in 2026.
- The anticipated slowdown is largely attributed to pricing pressures on Ozempic and Wegovy.
- The company still anticipates significant growth in the overall diabetes and obesity care market.
- Novo Nordisk expects sales growth of 18 percent to 26 percent for 2024.
The company’s outlook, released today, points to increasing pressure on the prices of its highly sought-after medications. Ozempic and Wegovy,both based on the active ingredient semaglutide,have become household names-and sparked considerable debate-as effective tools for weight management. But that success is now bumping up against the realities of the pharmaceutical market.
What’s Driving the Forecast?
The anticipated price erosion is a key factor in Novo Nordisk’s revised projections. While demand for these drugs remains strong, the company acknowledges that increased competition and payer pushback could impact future revenue. Novo Nordisk still projects robust growth for 2024, estimating sales will increase between 18 percent and 26 percent this year.
